46 results about "Propionine" patented technology

The invention belongs to the technical field of biology, and particularly relates to an antibacterial peptide for inhibiting propionibacterium acnes and application of the antibacterial peptide. The antibacterial peptide for inhibiting propionibacterium acnes is derived from marine organism hylophila, and the amino acid sequence of the antibacterial peptide is shown as SEQ ID NO.1. The amino acid sequence is novel, has remarkable antibacterial activity on propionibacterium acnes, has the advantages of low hemolysis toxicity, low cytotoxicity and high safety, and can be used for preparing the antibacterial peptide for inhibiting propionibacterium acnes. Due to the characteristics, the compound has huge application potential in the aspect of treating acnes caused by propionibacterium acnes or removing acnes.

This present disclosure provides adeno-associated viral vectors, recombinant adeno-associated virus (rAAV), and methods of their use in gene therapy for treating propionic acidemia (PA). Also provided are pharmaceutical compositions comprising a recombinant adeno-associated virus of the invention and a pharmaceutically acceptable carrier or excipient. These pharmaceutical compositions may be useful in gene therapy for the treatment of PA caused by mutations in propionyl-CoA carboxylase α-subunit (PCCA) or mutations in propionyl-CoA carboxylase β-subunit (PCCB).

This present disclosure provides adeno-associated viral vectors, recombinant adeno-associated virus (rAAV), and methods of their use in gene therapy for treating propionic acidemia (PA). Also provided are pharmaceutical compositions comprising a recombinant adeno-associated virus of the invention and a pharmaceutically acceptable carrier or excipient. These pharmaceutical (compositions may be useful in gene therapy for the treatment of PA caused by mutations in propionyl-CoA carboxylase α-subunit (PCCA) or mutations in propionyl-CoA carboxylase β-subunit (PCCB).

The invention relates to a sodium propionate-containing hydrate inhibitor for guaranteeing flow of a carbon dioxide conveying pipeline, which comprises sodium propionate, glycine, polyvinyl pyrrolidone and methanol, and the sodium propionate, the glycine, the polyvinyl pyrrolidone and the methanol are mixed with a sodium chloride solution serving as a solvent, so that the sodium propionate, the glycine, the polyvinyl pyrrolidone and the methanol are mixed according to the molar percentage as follows: 1-15 mol% of the sodium propionate, 1-15 mol% of the glycine, 0.1-1 mol% of the polyvinyl pyrrolidone and 5-60 mol% of the methanol. The sodium propionate, the glycine, the polyvinyl pyrrolidone and the methanol are compounded for use, so that the effect of a single inhibitor is enhanced, the application range is wider, a better inhibition effect is achieved at a lower concentration, and the generation of carbon dioxide hydrate can be better inhibited. The mixed use reduces the cost of the inhibitor, reduces the use amount of the mixture, and weakens the toxicity and pollution of the inhibitor.

The present disclosure provides methods of treating skin acne-like rash in a subject in need thereof. The method comprises applying an effective amount of picosterone-17 alpha-propionate to the surface of the subject. The acne-like rash may include papules, pustules, nodules, scabs, cysts, or any combination thereof on an affected area of the subject. An effective amount of the picosterone-17 [alpha]-propionate can be administered in a surface pharmaceutical formulation comprising the picosterone-17 [alpha]-propionate and one or more pharmaceutically acceptable carriers.

The present disclosure provides a method of treating hair loss in a subject in need thereof, comprising administering to the surface of the subject an effective amount of picosterone-17a-propionate and an effective amount of minoxidil. The present disclosure also provides surface pharmaceutical formulations comprising picosterone-17a-propionate, minoxidil, and one or more pharmaceutically acceptable carriers.

This invention discloses a method for enhancing the antibacterial activity of Propionibacterium freudenreichii subsp. shermanii metabolites by adding a surfactant to a culture medium. The method uses Propionibacterium freudenreichii subsp. shermanii NBRC No. 12426 as the experimental strain and Pichia anomala SICC 2.894 as the indicator strain. A surfactant is added to the fermentation medium to enhance the antibacterial activity of the metabolites of Propionibacterium freudenreichii subsp. shermanii against the indicator strain Pichia anomala. Based on the culture conditions and method of Propionibacterium freudenreichii subsp. shermanii in this invention, the optimal concentration of the surfactant Tween-80 is selected as 0.3%, which significantly enhances the antibacterial activity of the metabolites of Propionibacterium freudenreichii subsp. shermanii.

The application belongs to the technical field of microorganisms, and provides application of Propionibacterium freudenreichii subsp. shermanii in preparation of products for improving constipation and depression, wherein the Propionibacterium freudenreichii subsp. shermanii NHNK-616 is preserved in the China Center for Type Culture Collection on July 1, 2024, and the preservation number is CCTCC NO: M 20241429. The inventors find that NHNK-616 has the functions of promoting 5-HT secretion, up-regulating intestinal aquaporin and brain-derived neurotrophic factor genes, metabolically producing gamma-aminobutyric acid, inhibiting growth of Candida albicans, inhibiting hypha formation of Candida albicans, combining with hypha of Candida albicans, and up-regulating expression of intestinal defensin and mucin genes, and therefore can be used for preparing products for improving constipation and depression.

A method of treating or ameliorating cataract surgical complications is provided. The method comprises administering to a subject in need thereof a nanoparticle of beclosone propionate (CLOBETASOL PROPIONATE). The method comprises administering to the subject in need thereof a nanoparticle of beclosone propionate.

1. Name of the product in this design: Packaging Bottle (Liv-Clobetasol Propionate Liniment). 2. Purpose of this design: As a packaging bottle. 3. The key design features of this product are the combination of shape and pattern. 4. The image or photograph that best illustrates the design's key points: a 3D model.

This invention relates to fluticasone propionate cream, belonging to the field of topical pharmaceutical preparations. By using a mixed solvent of hexanediol and propylene glycol, along with a composite stabilizer, this invention solves the problem in existing fluticasone propionate creams where inappropriate intradermal retention leads to insufficient therapeutic efficacy. Simultaneously, it ensures the stability of the cream; the cream of this invention remains stable under high temperature, high temperature, light, low temperature, and freeze-thaw conditions, with no significant increase in related substances. The preparation process of the fluticasone propionate cream of this invention is simple and suitable for industrial production.

The invention discloses a beclomethasone propionate suspension for inhalation, which belongs to the technical field of chemical medicinal preparations, and the beclomethasone propionate suspension for inhalation comprises beclomethasone propionate, beclomethasone propionate monohydrate, a surfactant, an osmotic pressure regulator and water for injection. According to the invention, a proper amount of beclomethasone dipropionate monohydrate is added into the prescription as a stabilizer, so that the problems of beclomethasone dipropionate particle size increase, easy agglomeration, low fine particle dosage and the like in the preparation process are effectively solved, the preparation process is simple, and the reproducibility is good.

The present application provides a method for preparing a fosinopril sodium intermediate, comprising using propionic acid-1-bromoisobutyl ester instead of propionic acid-1-chloroisobutyl ester disclosed in the prior art and reacting with [hydroxy(4-phenylbutyl)oxyphosphinyl]benzyl acetate, the method has higher non-corresponding selectivity, the yield of the target product levosimendan is significantly improved, and the product is easier to refine.

The invention provides a pharmaceutical composition containing picosterone-17 alpha-propionate, which is prepared from the following raw materials in parts by weight: 0.25 to 15 parts of picosterone-17 alpha-propionate, 1 to 5 parts of medicinal matrix, 8.75 to 80 parts of pharmaceutically acceptable solvent and 20 to 90 parts of pharmaceutically acceptable water, and the pH value of the pharmaceutical composition is 3.0 to 5.0. The pharmaceutically acceptable solvent is isopropanol or a composition of isopropanol and other solvents, and the weight percentage of the pharmaceutically acceptable water is greater than 20%. The invention further provides a preparation method and application of the pharmaceutical composition containing the picosterone-17alpha-propionate, the pharmaceutical composition is more beneficial to the active ingredients to play roles, and irritation and side effects caused by pharmaceutical auxiliary materials in the pharmaceutical composition are reduced.

This invention discloses a pharmaceutical composition and its application, characterized by comprising tebufenozide-7-propionate (W6) and a CDK4 / 6 inhibitor. The pharmaceutical composition is used in the preparation of drugs for treating drug-resistant tumors, specifically breast cancer. Low concentrations (0.1 µM–1.0 µM) of W6 alone have no significant antitumor activity against breast cancer. However, W6 can significantly enhance the anti-breast cancer activity of CDK4 / 6 inhibitors when used in combination with them by inhibiting the drug efflux protein P-glycoprotein and regulating apoptosis and survival / proliferation signaling pathways.

The application discloses a method for efficiently preparing beta-amino propionic acid calcium from beta-amino propionitrile, and comprises the following steps: beta-amino propionitrile and a calcium salt solution are reacted in the presence of a catalyst and an additive, and microwave radiation is used to promote the reaction; after the reaction solution is filtered and deaminated, the solution is concentrated, cooled and alcohol crystallized to obtain beta-amino propionic acid calcium crystals which can be used for the production of calcium pantothenate; wherein the catalyst is a transition metal complex, and the additive is a phase transfer catalyst or a buffer metal salt. The application has the advantages of simple process, high yield and high reaction efficiency.

The disclosure relates to pharmaceutical formulations comprising of lidocaine and halobetasol propionate, methods of making such formulations, and methods of using such formulations in the treatment of hemorrhoids.

The invention belongs to the technical field of adhesive preparation, and particularly relates to a recyclable aziridine propionate adhesive as well as a preparation method and application thereof. The recyclable aziridine propionate adhesive is prepared from the following raw materials in parts by weight: 40 to 50 parts of aziridine propionate monomers; 20-25 parts by weight of an olefine acid monomer and 20-25 parts by weight of an acetylenic acid monomer. According to the recyclable adhesive provided by the invention, aziridine propionate monomers are taken as a matrix, olefine acid monomers and acetylenic acid monomers are added to generate dynamic bonds, the network density of a polymer is improved, hydroxyl is introduced into the matrix, so that the content of hydrogen bonds is increased, and the deformation resistance of the adhesive is improved; the problem of low bonding strength of aziridine propionate adhesives in the prior art is solved.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses a suspension for fluticasone propionate aerosol inhalation and a preparation method thereof. The suspension for fluticasone propionate aerosol inhalation provided by the invention is prepared from fluticasone propionate, isooctanol phosphate, a stabilizer, sodium dihydrogen phosphate, disodium hydrogen phosphate and an osmotic pressure regulator. According to the suspension for the fluticasone propionate aerosol inhalation provided by the invention, the foaming amount of the suspension is obviously reduced and the content uniformity of the suspension is improved by replacing the surfactant with the isooctanol phosphate, so that the product quality of the suspension for the fluticasone propionate aerosol inhalation is ensured.

The invention relates to the technical field of microorganisms and the field of medicine health, and particularly discloses propionibacterium freudenreichii subsp. Scheri PF310 for relieving obesity by regulating and controlling energy metabolism related hormones and application of the propionibacterium freudenreichii subsp. Scheri PF310. The Propionibacterium fredenreichii subsp. Sheermanii PF310 is separated from yak milk in Nanqu city, and the preservation number of the Propionibacterium fredenreichii subsp. Sheermanii PF310 is CGMCC (China General Microbiological Culture Collection Center) No. 31417. The invention also discloses a preparation method of the Propionibacterium fredenreichii subsp. Sheermanii PF310. Animal experiments prove that the Propionibacterium freudenreichii subsp. Scheri PF310 provided by the invention realizes a remarkable anti-obesity effect through a unique energy metabolism related hormone multi-target collaborative regulation mechanism, and has the outstanding advantages of strong strain specificity, still effective thermal inactivation, wide application prospect and the like; brand new probiotic resources and intervention strategies are provided for prevention and treatment of obesity.

The present invention relates to a PAR2 inhibitor, in particular to 1-piperidine propionic acid or to pharmaceutical compositions comprising it, for use in the treatment or prevention or to assist the treatment or prevention of PAR2-related pathological conditions.

The present invention relates to a method for treating or preventing a disease associated with a Propionibacterium acnes bacterium in a subject, said method comprising modulating, in particular reducing, the ratio of the amount of a newly identified class of Propionibacterium acnes bacterium, referred to as type alpha, to the amount of a newly identified class of Propionibacterium acnes bacterium, referred to as type #, in said subject, alpha type classes effectively define acne-related strains, and # type classes define non-acne-related strains.

Provided herein are, inter alia, compositions, systems, and methods for preventing or treating acne. Included are compositions, combinations, systems, and methods comprising at least one Propionibacterium acnes bacteriophage, at least one anti-acne compound, and a pharmaceutically acceptable carrier. Also included are compositions, combinations, and systems comprising a Propionibacterium acnes bacteriophage and an enzyme. Methods for preventing or treating acne are also provided.

The invention provides propionibacterium acnes and application thereof. Specifically, the invention provides the propionibacterium acnes B16, the propionibacterium acnes B16 is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.31705. The propionibacterium acnes B16 has the advantages that the propionibacterium acnes B16 can be used for preparing the propionibacterium acnes B16; the strain B16 provided by the invention is separated and identified from pancreatic cancer excision tissues of clinical pancreatic cancer patients by adopting a bacterial separation and identification method. In-vitro research finds that propionibacterium acnes can significantly inhibit the growth of pancreatic cancer cells. Animal experiment results show that the caudal vein or intratumor injection can significantly inhibit the growth of pancreatic cancer. The experimental result shows that the B16 strain has the effect of inhibiting the growth of the pancreatic cancer, and prompts that the B16 has potential to become a microbial candidate drug for treating the pancreatic cancer.

The invention discloses a propionibacterium bacteriophage, a lyase and application of the propionibacterium bacteriophage and the lyase, particularly, the propionibacterium bacteriophage still maintains ultra-high potency (1011PFU / mL) when MOI is equal to 0.1, bacteria are almost completely removed, the treatment efficiency and safety of the bacteriophage are improved, and further, the treatment effect of the propionibacterium bacteriophage is improved. The endotoxin content of the bacteriophage disclosed by the invention is far lower than the 5EU / (kg.h) standard required in 'Consensus of Phage Treatment Clinical Application Management Experts', and the bacteriophage is harmless to a human body, does not cause serious side effects, is suitable for acne patients of different ages and health conditions, and further, has no toxic or side effects. The bacteriophage provided by the invention can also split propionibacterium acnes from all parts of a body, has broad-spectrum splitting capacity, and increases the potential application range of acne treatment and the wide inhibition capacity of the bacteriophage.

Provided herein are compounds and pharmaceutical compositions of formula I where R1, R2, R3, R4, R5 and R6 are as described herein. Also provided pharmaceutically acceptable salts or stereoisomers of these compounds. In addition methods are provided for inhibiting the binding of an integrin to treat various pathophysiological conditions.

This invention discloses a method and its application for enhancing the antibacterial activity of *Propionibacterium f. reudenreichii* subsp. *shermanii* metabolites by adding carrageenan to a semi-solid culture medium. The method uses *Propionibacterium f. reudenreichii* subsp. *shermanii* NBRC No. 12426 as the experimental strain and *Pichia anomala* SICC 2.894 as the indicator strain. It discloses a method for enhancing the antibacterial activity of *Propionibacterium f. reudenreichii* subsp. *shermanii* metabolites against the indicator strain *Pichia anomala* by adding carrageenan to the culture medium. Based on the culture conditions and method of *Propionibacterium f. reudenreichii* subsp. *shermanii* in this invention, the optimal amount of carrageenan added is selected as 0.6%, which significantly enhances the antibacterial activity of the *Propionibacterium f. reudenreichii* subsp. *shermanii* metabolites.

The present invention relates to the topical pharmaceutical composition comprising about 0.001% w / w to about 1% w / w latanoprost and about 1% w / w to about 15% w / w cortexolone-17α-propionate and a pharmaceutically acceptable vehicle comprising one or more solvent and process of its preparation. The invention further relates to the method wherein the composition is suitable for preventing and / or treating hair loss and / or stimulating hair growth. in patients suffering from alopecia, in particular androgenic alopecia (AGA).

The present application relates to the field of microorganisms, and provides a propionibacterium acidifaciens BL8 with functions of reducing blood sugar and resisting aging, and application thereof, the propionibacterium acidifaciens BL8 is preserved in China General Microbiological Culture Collection Center on December 20, 2024, and the preservation number is CGMCC No.33134.The propionibacterium acidifaciens BL8 of the present application can inhibit DPP4 activity, promote INS-1 insulin secretion, inhibit acetylcholinesterase activity and superior cellulase activity.Can reduce blood sugar;Improve memory, prevent and relieve Alzheimer's disease;Promote cellulose absorption, improve constipation, and have high research and application value in reducing blood sugar and resisting aging.